Grant of Options
Faron Pharmaceuticals Ltd. has announced the grant of 180,000 share options under its 2019 Share Option Plan, exercisable between December 1, 2026, and December 1, 2031, with an exercise price of €2.26 per share. These options, which vest 25% annually over four years, represent 0.16% of the company's fully diluted share capital and were allocated to directors, persons discharging managerial responsibilities, and other personnel, including 180,000 options granted to Jurriaan Dekkers.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | December 02, 2025 at 09:00:00 EET |
TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company’s board has confirmed the grant of a total of 180,000 options over ordinary shares in the Company (“Options”) under the Company’s Share Option Plan 2019.
The Options have been allocated under the Share Option Plan 2019 and are exercisable between 1 December 2026 and 1 December 2031, vesting 25% per annum over four years. The exercise price for Options allocated under the Share Option plan is €2.26 per share, which is calculated based on the average price per share at which the ordinary shares in the Company have been traded on AIM for 90 days preceding the allocation date of 1 December 2025. The terms of the Share Option Plan 2019 are available on the Company’s website at https://faron.com/wp-content/uploads/2025/04/20250321_Share-Option-Plan-2019_Rules_EN_clean.pdf
The granted 180,000 Options entitle the option holders to subscribe for a total of 180,000 new ordinary shares in the Company, if exercised in full, and represent 0.16% of the fully diluted ordinary share capital of the Company.
Included in the number of Options granted are the following Options which were issued to directors, other persons discharging managerial responsibilities (“PDMRs”) and Company personnel:
Other PDMR
| Jurriaan Dekkers | 180,000 | |
| Total other PDMRs | 180,000 | |
| a. | Name | Jurriaan Dekkers |
| 2 | Reason for notification | |
| a. | Position/Status | Person discharging managerial responsibilities |
| b. | Initial notification/ Amendment | Initial notification |
| a. | Name | Faron Pharmaceuticals Oy |
| b. | LEI | 7437009H31TO1DC0EB42 |
| a. | Description of the financial instrument, type of instrument Identification Code | Options over new ordinary shares ISIN: FI4000153309 |
| b. | Nature of the transaction | Grant of options made under the Faron Share Option Plan 2019 |
| c. | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| €2.26 | 180,000 | |
| d. | Aggregated information - Aggregated Volume - Price | Nil |
| f. | Place of the transaction | Turku |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.